---
input_text: 'Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor
  in people with cystic fibrosis with no F508del CFTR variant: further analysis for
  the French compassionate use programme.'
raw_completion_output: |-
  primary_disease: Cystic Fibrosis
  medical_actions: Targeted approach for elexacaftor/tezacaftor/ivacaftor
  symptoms: No specific symptoms mentioned
  chemicals: Elexacaftor;Tezacaftor;Ivacaftor
  action_annotation_relationships: Targeted approach for elexacaftor/tezacaftor/ivacaftor TREATS no specific symptom IN Cystic Fibrosis
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Targeted approach for elexacaftor/tezacaftor/ivacaftor TREATS no specific symptom IN Cystic Fibrosis

  ===

extracted_object:
  primary_disease: MONDO:0009061
  medical_actions:
    - Targeted approach for elexacaftor/tezacaftor/ivacaftor
  symptoms:
    - No specific symptoms mentioned
  chemicals:
    - Elexacaftor
    - Tezacaftor
    - CHEBI:66901
  action_annotation_relationships:
    - subject: Targeted approach
      predicate: TREATS
      object: no specific symptom
      qualifier: MONDO:0009061
      subject_extension: elexacaftor/tezacaftor/ivacaftor
named_entities:
  - id: MONDO:0009061
    label: Asthma; COPD; Asthma-COPD overlap; Cystic Fibrosis (CF)
  - id: MONDO:0004979
    label: Asthma
  - id: MONDO:0011751
    label: COPD
  - id: MONDO:0004822
    label: Bronchiectasis
  - id: CHEBI:50329
    label: Tris(2-carboxyethyl)phosphine (TCEP)
  - id: CHEBI:63016
    label: NP40
  - id: CHEBI:33349
    label: Hyaluronic acid (HA)
  - id: CHEBI:28864
    label: Tobramycin
  - id: CHEBI:16336
    label: Hyaluronic acid
  - id: HP:0011947
    label: respiratory infections
  - id: MAXO:0001175
    label: liver transplantation
  - id: CHEBI:35627
    label: beta-lactams
  - id: HP:0012378
    label: fatigue
  - id: HP:0002094
    label: dyspnea
  - id: CHEBI:66901
    label: Ivacaftor
